Abstract
Rapid advances in synthetic biology are driving the development of genetically engineered microbes as therapeutic agents for a multitude of human diseases, including cancer. The immunosuppressive microenvironment of solid tumors, in particular, creates a favorable niche for systemically administered bacteria to engraft and release therapeutic payloads. However, such payloads can be harmful if released outside the tumor in healthy tissues where the bacteria also engraft in smaller numbers. To address this limitation, we engineer therapeutic bacteria to be controlled by focused ultrasound, a form of energy that can be applied noninvasively to specific anatomical sites such as solid tumors. This control is provided by a temperature-actuated genetic state switch that produces lasting therapeutic output in response to briefly applied focused ultrasound hyperthermia. Using a combination of rational design and high-throughput screening we optimize the switching circuits of engineered cells and connect their activity to the release of immune checkpoint inhibitors. In a clinically relevant cancer model, ultrasound-activated therapeutic microbes successfully turn on in situ and induce a marked suppression of tumor growth. This technology provides a critical tool for the spatiotemporal targeting of potent bacterial therapeutics in a variety of biological and clinical scenarios.
Introduction
Genetically engineered bacteria represent a promising class of "living pharmacies" due to their natural ability to home to and colonize the immunosuppressive, necrotic cores of solid tumors—regions often inaccessible to conventional systemic therapies. However, a significant safety challenge persists: these bacteria can also engraft in healthy organs like the liver and spleen. Continuous secretion of potent therapeutic payloads in these off-target sites risks severe systemic toxicity.
To overcome this, spatiotemporal control is required. While chemical or light-based triggers have been explored, they often lack the necessary precision or tissue penetration depth. This research utilizes focused ultrasound (FUS) to provide a noninvasive means of heating deep-seated tissues with sub-millimeter precision, serving as a remote trigger to activate engineered microbes specifically within the tumor microenvironment.
Methods and Circuit Design
The therapeutic chassis used in this study is E. coli Nissle 1917 (EcN), a safe probiotic strain. The core innovation is a multi-layered genetic circuit designed for thermal sensitivity and memory:
- Thermal Transducer: The team identified TcI42, a temperature-sensitive repressor that remains bound to DNA at $37^\circ\text{C}$ but releases at $42^\circ\text{C}$ (mild hyperthermia).
- State Switch: To avoid the need for continuous heating, a "memory" switch was implemented using Bxb1 integrase. A brief heat pulse triggers Bxb1 expression, which permanently inverts a DNA segment containing a promoter, locking the cell into an "ON" state.
- Circuit Optimization: To minimize baseline "leakiness," the researchers combined rational design (incorporating RNA thermometers and terminators) with high-throughput library screening of $\sim10^7$ variants to optimize induction ratios.
- Therapeutic Payload: The optimized circuit was linked to the secretion of nanobodies targeting CTLA-4 and PD-L1, key checkpoints in cancer immunotherapy.
Key Insights: Optimization and Viability
- Memory is Essential: By utilizing an integrase-based switch, a single 1-hour FUS treatment can provide weeks of continuous therapeutic output, making the treatment clinically viable.
- Pulsatile Heating: Continuous exposure to $42^\circ\text{C}$ can reduce bacterial viability. A pulsatile scheme (e.g., 5 minutes on, 5 minutes off) was found to maintain high induction levels while significantly improving bacterial survival.
- Hybrid Engineering Strategy: Achieving a >100-fold induction ratio required a combination of massive library screening and targeted modifications of secondary mRNA structures and replication origins.
Results and Efficacy
In A20 murine tumor models, the engineered bacteria demonstrated high specificity and efficacy:
- Localized Activation: Over 20% of bacteria within the tumor were successfully switched to the "ON" state following FUS, while activation in the liver and spleen remained minimal (<5%).
- Tumor Suppression: Mice treated with FUS-activated therapeutic EcN showed significant reduction in tumor growth compared to controls receiving wild-type bacteria or FUS alone.
- Sustained Therapeutic Output: Once triggered, the bacteria remained active and continued to suppress tumor growth for at least two weeks without further intervention.
Discussion and Future Directions
While promising, several hurdles remain for clinical translation. Current FUS setups may result in non-uniform heating, potentially leaving pockets of non-activated bacteria. Scaling to human patients will require MRI-guided FUS systems for precise targeting of larger, deeper tumors. Future research may also explore combining these ultrasound-controllable bacteria with other modalities, such as CAR-T cell therapy, to further enhance the immune response within the tumor microenvironment.
Summary updated